Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2010 | 1 |
2011 | 1 |
2012 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean
m bornhauser[Author]
(73 results)?
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.
Bone Marrow Transplant. 2012 Sep;47(9):1171-7. doi: 10.1038/bmt.2011.242. Epub 2011 Dec 12.
Bone Marrow Transplant. 2012.
PMID: 22158386
Clinical Trial.
A total number of 75 patients with AML in CR were treated with 3 14 g/m(2) treosulfan and 5 30 mg/m(2) fludarabine, followed by matched sibling or unrelated SCT. ...
A total number of 75 patients with AML in CR were treated with 3 14 g/m(2) treosulfan and 5 30 mg/m(2) fludarabine, followed b …
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.
Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, Stadler M, Uharek L, Stelljes M, Knop S, Wulf G, Trenschel R, Vucinic V, Dittmann H, Faul C, Vogel W, Kanz L, Bunjes D.
Bethge WA, et al. Among authors: bornhaeuser m.
Blood. 2010 Sep 9;116(10):1795-802. doi: 10.1182/blood-2010-02-270538. Epub 2010 Jun 7.
Blood. 2010.
PMID: 20530284
Free article.
Clinical Trial.
Forty patients were enrolled in this phase 2 study combining radioimmunotherapy (RIT) using yttrium-90-ibritumomab-tiuxetan (15 MBq [0.4 mCi]/kg) with reduced-intensity conditioning (RIC) using fludarabine (90 mg/m(2)) and 2 Gy total body irradiation followed by allogeneic …
Forty patients were enrolled in this phase 2 study combining radioimmunotherapy (RIT) using yttrium-90-ibritumomab-tiuxetan (15 MBq [0.4 mCi …
Item in Clipboard
Cite
Cite